Literature DB >> 2446044

Topographical and conformational epitopes of bovine papillomavirus type 1 defined by monoclonal antibodies.

L M Cowsert1, P Lake, A B Jenson.   

Abstract

Monoclonal antibodies (MAbs) were generated against sodium dodecyl sulfate-disrupted bovine papillomavirus type 1 (BPV-1). When screened by enzyme-linked immunosorbent assay (ELISA) on intact and disrupted BPV-1, -2, and deer papillomavirus, three patterns of reactivity were defined: reactivity only with intact virus, with both intact and disrupted virus, and only with disrupted virus. On the basis of ELISA results, the topographical location and requirement for conformation for immunoreactivity of epitopes was defined as external conformational, external linear, and internal linear. Cross-reactivity of MAbs with other papillomavirus types was analyzed by immunofluorescence on warts from different species. Type-specific, BPV-1 and/or -2 cross-reactive, broadly cross-reactive, and genus-specific MAbs were identified. MAb reactivity with structural polypeptides of BPV-1 was analyzed by Western blot. MAbs reactive with epitopes defined as conformational by ELISA did not react in Western blot. All MAbs reactive in Western blot reacted with the major capsid protein (MCP) [55 kilodalton (kDa)], demonstrating that the MCP carries both type-specific and cross-reactive epitopes. Most MAbs reactive with the MCP were cross-reactive with structural polypeptides of 48 and 96 kDa, demonstrating the immunologic relatedness of these three polypeptides.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446044

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction.

Authors:  T S Baker; W W Newcomb; N H Olson; L M Cowsert; C Olson; J C Brown
Journal:  Biophys J       Date:  1991-12       Impact factor: 4.033

2.  Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope.

Authors:  S A Jenison; X P Yu; J M Valentine; D A Galloway
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11.

Authors:  N D Christensen; J W Kreider; N M Cladel; S D Patrick; P A Welsh
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

4.  Antibody-mediated neutralization in vivo of infectious papillomaviruses.

Authors:  N D Christensen; J W Kreider
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

5.  Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses.

Authors:  L Dillner; P Heino; J Moreno-Lopez; J Dillner
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

6.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

7.  Development of type-specific and cross-reactive serological probes for the minor capsid protein of human papillomavirus type 33.

Authors:  C Volpers; M Sapp; C A Komly; P Richalet-Secordel; R E Streeck
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts.

Authors:  L M Cowsert; M C Fox; G Zon; C K Mirabelli
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins.

Authors:  Y Sun; K V Shah; M Müller; N Muñoz; X F Bosch; R P Viscidi
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.